ERIS Lifesciences Ltd (ERIS) is currently trading at 1,150.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Eris Lifesciences Limited develops, manufactures and markets branded pharmaceutical products, primarily in chronic, sub-chronic and acute therapies including diabetes, cardiology, vitamins and gastroenterology. Its domestic branded-formulations business contributes the core revenue base, complemented by sterile injectables through Swiss Parenterals and biologics manufacturing through Eris Bionxt. The company’s domestic branded-formulations revenue grew 14.1% year-on-year in Q2 FY27 and 14.2% in H1, with all major reported therapies matching or exceeding Indian pharmaceutical-market growth. Excluding the Zorvia portfolio transfer, Q2 domestic growth was 16.5%, indicating that underlying momentum remained stronger than the headline number. Diabetes is a major strategic concentration, contributing 37.3% of Eris’s Q2 portfolio versus 9.5% for the Indian pharmaceutical market. The company is combining insulin manufacturing with an in-house recombinant semaglutide program, regulatory approvals for Phase 1 and Phase 3 trials, and three additional analogues planned for the regulatory pathway. Consolidated Q2 revenue increased 12.6% to ₹892 crore, while adjusted PAT rose 17.5% to ₹158 crore. Reported PAT growth of 39.2% benefited from a positive tax impact associated with the subsidiary merger, so adjusted earnings provide a more representative view of underlying profitability. Profitability remains strong but faces investment-related pressure: consolidated EBITDA margin declined to 34.7% from 36.4%, while Swiss Parenterals’ margin fell to 25.0% during EU CAPA execution. Management expects gross-margin improvement from Zorvia licensing, Bhopal commercialization and eventual manufacturing migration, with new assets expected to contribute from next year.

Over the past 52 weeks, ERIS Lifesciences Ltd has traded between a low of ₹1,069.00 and a high of ₹1,737.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

ERIS Lifesciences Ltd has a market capitalization of approximately 16,145.01. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

ERIS Lifesciences Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 21.57 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 16,145.01 Cr, ERIS Lifesciences Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

ERIS Lifesciences Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of ERIS Lifesciences Ltd is 21.57. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Eris Lifesciences is scheduled to consider and report its Q2 FY27 results on October 26, 2026.

The call is scheduled for Wednesday, July 29, 2026 at 4:30 PM IST.

Eris Lifesciences declared an interim dividend of ₹7.21 per share (721%) for FY26-27.

Operating revenue rose 7% YoY to INR 757 crore, EBITDA increased 8% to INR 274 crore, and net profit rose to INR 279 crore, aided by a deferred tax gain.